



**REORGANISATION
AND A NEW APPOINTMENT
FOR NORGINE**

7 December 2004

Norgine, the independent European specialty pharmaceutical company, has announced a re-organisation that will take effect on the 4th January 2005 to support its growth strategy.

The company has established five Sales and Marketing Business Units in place of its current European regional structure. The new Sales and Marketing Business Units are structured as follows: Germany, Austria and Switzerland; France, Italy, Algeria and Tunisia; UK, Ireland, Australasia and South Africa; Medium-Sized and Emerging Markets; and USA Operations.

The re-organisation has led to an external appointment; Kenneth Scrimgeour as Vice-President of the UK, Ireland, Australasia and South Africa Business Unit.

Kenneth Scrimgeour joins Norgine following 20 years at Schering-Plough in a variety of senior sales and marketing roles in Europe and the USA.

Morten Brandt, Luk Herten and Hugh Poulton are all promoted to Vice-President Germany, Austria, Switzerland; France, Italy, Algeria and Tunisia; and Medium-Sized and Emerging Markets respectively.

Commenting on the re-organisation Peter Stein, Chief Executive Officer said: "With this new structure in place, Norgine is in a strong position to be the European 'partner of choice' for developing, manufacturing and marketing pharmaceutical products, and also for expansion into new markets".

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for almost 100 years and has a presence in all the major European markets. In 2003 Norgine's sales were €133 million, the 17th consecutive year of double-digit growth. The company employs 850 people, of which 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets eight products in its key therapeutic areas e.g. Movicol for the treatment of chronic constipation and faecal impaction, Klean-Prep for bowel preparation prior to colonoscopy and Fivasa for the treatment of ulcerative colitis and Crohn's disease.

Norgine has an active Research and Development effort and currently has nine products at various stages of clinical development including NRL994, a bowel preparation product. A European submission for NRL994 has already been filed and the company expects to submit an NDA early in 2005.

Norgine has two manufacturing sites; Hengod in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Louise Blakeborough, Chapter Five
T: +44 (0) 1306 731800
E: lblakeborough@chapterfive.co.uk